摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Cyclohexyl-3,3-dimethyl-butyramid | 7473-22-5

中文名称
——
中文别名
——
英文名称
N-Cyclohexyl-3,3-dimethyl-butyramid
英文别名
3,3-dimethyl-butyric acid cyclohexylamide;3.3-Dimethyl-N-cyclohexyl-butyramid;3,3-Dimethyl-buttersaeure-cyclohexylamid;N-cyclohexyl-3,3-dimethylbutanamide
N-Cyclohexyl-3,3-dimethyl-butyramid化学式
CAS
7473-22-5
化学式
C12H23NO
mdl
MFCD02860287
分子量
197.321
InChiKey
QKFUDYIYOWGUJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.916
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    3,3-二甲基-1-丁酸草酰氯三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 12.0h, 生成 N-Cyclohexyl-3,3-dimethyl-butyramid
    参考文献:
    名称:
    基于叔丁基乙酸的 LMOG 的刺激响应凝胶——在海洋溢油修复、染料去除和重金属传感中的应用
    摘要:
    已经合成了含有结构主链、氢键连接基和大端基的叔丁基乙酸酰胺(TBA1-TBA6),并探索了其用于燃料油和有机溶剂的凝胶化。我们之前报道的基于新戊酰胺的相选择性有机凝胶剂(PSOG)强调了叔丁基在驱动组装凝胶化方面的重要性。对两组化合物进行了仔细检查,并探讨了新合成的系列化合物中额外的亚甲基的影响(对凝胶行为、单晶结构、负责凝胶的非共价相互作用、形态、染料吸收等)。。化合物TBA1–TBA6也可用于检测水介质中存在的重金属离子和过渡金属离子。当以粉末形式和溶液形式添加时,它们在双相系统(油-海水)存在下表现出油的相选择性凝胶化,因此成为控制水体中溢油的绝佳候选者。总体而言,这两个库形成了一类用于成功有机凝胶化行为的最小分子。
    DOI:
    10.1039/d3sm00960b
点击查看最新优质反应信息

文献信息

  • Nickel-catalyzed transamidation of aliphatic amide derivatives
    作者:Jacob E. Dander、Emma L. Baker、Neil K. Garg
    DOI:10.1039/c7sc01980g
    日期:——
    in the transamidation of primary amides, the transamidation of secondary amides has remained underdeveloped, especially when considering aliphatic substrates. Herein, we report a two-step approach to achieve the transamidation of secondary aliphatic amides, which relies on non-precious metal catalysis. The method involves initial Boc-functionalization of secondary amide substrates to weaken the amide
    转酰胺基化或一种酰胺向另一种酰胺的转化是有机合成中的长期挑战。尽管伯酰胺的氨基转移已经取得了显着进展,但仲酰胺的氨基转移仍未得到很好的发展,特别是在考虑脂肪族底物的情况下。在本文中,我们报告了一种分步进行的方法,以实现仲脂族酰胺的氨基转移,该方法依赖于非贵金属催化。该方法涉及仲酰胺底物的初始Boc官能化,以削弱酰胺C–N键。随后在合适的胺偶联剂存在下用镍催化剂处理,然后得到净的转酰胺基产物。该转化在一系列底物上以合成有用的产率进行。一系列竞争实验描述了选择性模式,该模式应影响未来的合成设计。此外,带有可差向立构立体中心的Boc活化仲酰胺衍生物的转氨基作用强调了该方法的温和性和合成实用性。这项研究为迄今为止报道的仲酰胺转酰胺基团的经典问题提供了最通用的解决方案。
  • PYRIDO[3,4-B]INDOLES AND METHODS OF USE
    申请人:Medivation Technologies, Inc.
    公开号:US20130190308A1
    公开(公告)日:2013-07-25
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。其中描述了吡啶并[3,4-b]吲哚,以及包含该化合物的药物组合物和使用该化合物进行各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
  • PYRIDO[4,3-B]INDOLES AND METHODS OF USE
    申请人:MEDIVATION TECHNOLOGIES, INC.
    公开号:US20130190344A1
    公开(公告)日:2013-07-25
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。其中描述了吡啶并[4,3-b]吲哚,以及包含该化合物的药物组合物和使用该化合物进行各种治疗应用的方法,包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
  • N-Aryl and N-cycloalkyl neoalkanamide insect repellents
    申请人:Colgate-Palmolive Company
    公开号:EP0499992A1
    公开(公告)日:1992-08-26
    N-monosubstituted neoalkanamides of 11 to 14 carbon atoms wherein the substituent on the amide nitrogen is cyclic (aromatic or cycloaliphatic, such as aryl or cycloalkyl) and of at least five carbon atoms, have been discovered to be insect repellent, providing that any aromatic substituent is unsubstituted at the ortho position and that when the neoalkanoyl moiety is pivaloyl the total number of carbon atoms in the N-cyclic neoalkanamide is at least 12. Such neoalkanamides are useful as repellents against cockroaches, including American, German and Oriental cockroaches, and are also effective against mosquitoes (both Anopheles and Aedes), black flies and carpenter ants, and to some extent against deer ticks. They may be applied to areas, locations and items which are desirably to be kept free of such insects, with applications being direct or of solutions or emulsions thereof, preferably by spraying, or in detergent compositions or other products to be applied to such areas, etc. Because the described neoalkanamides are desirably substantive to surfaces and are usually in liquid state, they give long lasting repellency to such areas, etc., and tests have shown them to be sufficiently long lasting.
    已发现 11 至 14 个碳原子的 N-单取代新烷酰胺,其中酰胺氮上的取代基为环状(芳香族或环脂肪族,如芳基或环烷基)且至少有 5 个碳原子,具有驱虫剂的作用,条件是任何芳香族取代基在正交位置上未被取代,并且当新烷酰基为新戊酰基时,N-环新烷酰胺中的碳原子总数至少为 12 个。这种新烷酰胺可用作蟑螂(包括美洲、德国和东方蟑螂)的驱避剂,对蚊子(包括按蚊和伊蚊)、黑蝇和木匠蚁也有效,在一定程度上对鹿蜱也有效。可将它们施用在希望没有此类昆虫的区域、地点和物品上,施用方式可以是直接施用,也可以是其溶液或乳液的施用,最好是通过喷洒,或在洗涤剂组合物或其他产品中施用到这些区域等。由于所述新烷酰胺对表面具有良好的吸附性,而且通常呈液态,因此它们对这些区域等具有持久的驱避作用,测试表明它们具有足够的持久性。
  • INHIBITORS OF INFLUENZA VIRUSES REPLICATION
    申请人:Vertex Pharmaceuticals Inc.
    公开号:EP3141252A1
    公开(公告)日:2017-03-15
    Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法,包括向所述生物样本或患者施用有效量的结构式(I)所代表的化合物: 或其药学上可接受的盐,其中结构式(IA)的值如本文所述。一种化合物由结构式(IA)或其药学上可接受的盐代表,其中结构式(IA)的值如本文所述。药物组合物包含有效量的此类化合物或其药学上可接受的盐,以及药学上可接受的载体、佐剂或载体。
查看更多